Autoreactivity in HIV-1 broadly neutralizing antibodies: Implications for their function and induction by vaccination

Current Opinion in HIV and AIDS

Volumn 9, Issue 3, 2014, Pages 224-234

  Verkoczy, Laurent ^a   Diaz, Marilyn ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Autoreactivity; broadly neutralizing antibodies; immune tolerance; polyreactivity; somatic hypermutation

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS 1 BROADLY NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

COMPLEMENTARITY DETERMINING REGION; CORRELATION ANALYSIS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; LIPID MEMBRANE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; AUTOIMMUNITY; BIOSYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; AUTOIMMUNITY; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE;

EID: 84898463606     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000049     Document Type: Review

References (108)

1. Plotkin S. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-1065.
2. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV. Nature 2003; 422:307-312.
3. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
4. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Path 2009; 5:e1000433.
5. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-84.
6. Simek MD, Rida W, Priddy FH, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337-7348.
7. Gray ES, Madiga MC, Hermanus T, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85:4828-4840.
8. Tomaras GD, Binley JM, Gray ES, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 2011; 85:11502-11519.
9. Mikell I, Sather DN, Kalams SA, et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7:e1001251.
10. Schied JF, Mouquet H, Feldhahn N, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 2009; 343:65-67.
11. Morris L, Chen X, Alam M, et al. Isolation of a human HIV gp41 membrane proximal region neutralizing antibody by antigen-specific B cell sorting. PLoS One 2011; 6:e23532.
12. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
13. Bonsignori M, Hwang KK, Chen X, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011; 85:9998-10009.
14. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377.
15. Liao HX, Levesque MC, Nagel A, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 2009; 158:171-179.
16. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 2013; 254:225-244.
17. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333:1633-1637.
18. Walker LM, Simek MD, Priddy F, et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Path 2010; 6:e1001028.
19. Bonsignori M, Montefiori DC, Wu X, et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 2012; 86:4688-4692.
20. Doria-Rose NA, Louder MK, Yang Z, et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol 2012; 86:3393-3397.
21. Liao H-X, Lynch R, Zhou Z, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469-476.
22. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393:705-711.
23. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420:678-682.
24. Schief WR, Ban YE, Stamatatos L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 2009; 4:431-440.
25. Stamatatos L, Morris L, Burton DR, et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nature Med 2009; 15:866-870.
26. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by Plasma Antigp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-12463.
27. Liao HX, Chen X, Munshaw S, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 2011; 208:2237-2249.
28. Burton DR, Poignard P, Stanfield RL, et al. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012; 337:183-186.
29. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012; 37:412-425.
30. McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 2013; 210:209-223.
31. Schiffner T, Sattentau QJ, Dorrell L. Development of prophylactic vaccines against HIV-1. Retrovirology 2013; 10:72-88.
32. Kong L, Sattentau QJ. Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J AIDS Clin Res 2012; S8:3.
33. Moir S, Fauci AS. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev 2013; 254:207-224.
34. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific auto-reactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-1908.
35. Verkoczy L, Kelsoe G, Moody MA, et al. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 2011; 23:383-390.
36. Haynes BF, Moody MA, Verkoczy L, et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005; 14:59-67.
37. Kaye BR. Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). Ann Intern Med 1989; 111:158-167.
38. Barthel HR, Wallace DJ. False-positive human immunodeficiency virus testing in patients with lupus erythematosus. Semin Arthritis Rheum 1993; 23:1-7.
39. Mylonakis E, Paliou M, Greenbough TC, et al. Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. Arch Intern Med 2000; 160:2386-2388.
40. Palacios R, Santos J, Valdivielso P, et al. Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature. Lupus 2002; 11:60-63.
41. Calza L, Manfredi R, Colangeli V, et al. Systemic and discoid lupus erythe-matosus in HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS 2003; 14:356-359.
42. Verkoczy L, Diaz M, Holl TM, et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010; 107:181-186.
43. L knockin mice reveals multiple tolerance controls. J Immunol 2011; 187:3785-3797.
44. Chen Y, Zhang J, Hwang KK, et al. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol 2013; 191: 1260-1275.
45. Doyle-Cooper C, Hudson KE, Cooper AB, et al. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV anti body 4E10. J Immunol 2013; 191:3186-3191.
46. Finton KA, Larimore K, Larman HB, et al. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog 2013; 9:e1003639.
47. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989; 337:562-566.
48. Hartley SB, Crosbie J, Brink R, et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 1991; 353:765-769.
49. Chen C, Nagy Z, Radic MZ, et al. The site and stage of anti-DNA B-cell deletion. Nature 1995; 373:252-255.
50. Goodnow CC. Transgenic mice and analysis of B-cell tolerance. Ann Rev Immunol 1992; 10:489-518.
51. Yang G, Holl TM, Liu Y, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 2013; 210:241-256.
52. Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008; 28:18-28.
53. Lang J, Jackson M, Teyton L, et al. B-cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane bound antigen. J Exp Med 1996; 184:1685-1697.
54. Ota T, Doyle-Cooper C, Cooper AB, et al. Anti-HIV B cell lines as candidate vaccine biosensors. J Immunol 2012; 189:4816-4824.
55. Bonsignori M, Alam SM, Liao HX, Verkoczy L, et al. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 2013; 20:532-539.
56. Haynes BF, Kelsoe G, Harrison SC, et al. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotech 2012; 30:423-433.
57. Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491:406-412.
58. Kepler TB, Perelson AS. Somatic hypermutation in B cells: an optimal control treatment. J Theor Biol 1993; 164:37-64.
59. Zhang J, Shakhnovich EI. Optimality of mutation and selection in germinal centers. PLoS Comput Biol 2010; 6:e1000800.
60. Shlomchik M, Mascelli M, Shan H, et al. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J Exp Med 1990; 171:265-292.
61. Tiller T, Tsuiji M, Yurasov S, et al. Autoreactivity in human IgG+ memory B cells. Immunity 2007; 26:205-213.
62. Mietzner B, Tsuiji M, Scheid J, et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA 2008; 105:9727-9732.
63. Moore PL, Gray ES, Wibmer CK, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012; 18:1688-1692.
64. Hoot S, McGuire AT, Cohen KW, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bnAbs. PLoS Path 2013; 9:e1003106.
65. Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent neutralization. Cell 2013; 153:126-138.
66. Mouquet H, Scheid JF, Zoller MJ, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467:591-595.
67. Verkoczy L, Chen Y, Zhang J, et al. Induction of HIV-1 broad neutralizing antibodies in 2F5 knockin mice: selection against MPER-associated auto-reactivity limits T-dependent responses. J Immunol 2013; 191:2538-2550.
68. Diaz M, Klinman N. Relative roles of somatic and Darwinian evolution in shaping the antibody response. Immunol Res 2000; 21:89-102.
69. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002; 2:323-335.
70. Hardy RR. B-1 B cell development. J Immunol 2006; 177:2749-2754.
71. Pujanauski LM, Janoff EN, McCarter MD, et al. Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 2013; 110:1422-1427.
72. Chen J, Frey G, Peng H, et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol 2014; 88:1249-1258.
73. Ota T, Doyle-Cooper C, Cooper AB, et al. B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. J Immunol 2013; 191: 3179-3185.
74. Ota T, Aoki-Ota M, Tsunoda K, et al. Auto-reactive B cells against peripheral antigen, desmoglein 3, escapefrom tolerance mechanism. Int Immunol 2004; 16:1487-1495.
75. Aplin BD, Keech CL, de Kauwe AL, et al. Tolerance through indifference: autoreactive B cells to the nuclear antigen La show no evidence of tolerance in a transgenic model. J Immunol 2003; 171:5890-5900.
76. Chen J, Lansford R, Stewart V, et al. RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. Proc Natl Acad Sci USA 1993; 90:4528-4532.
77. Bonsignori M, Wiehe K, Grimm SK, et al. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest 2014; In press.
78. Zhu P, Liu J, Bess J Jr, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441:847-852.
79. Liu J, Bartesaghi A, Borgnia MJ, et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008; 455:109-113.
80. West AP Jr, Diskin R, Nussenzweig MC, et al. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 2012; 109:E2083-2090.
81. Alam SM, Morelli M, Dennison SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009; 106:20234-20239.
82. Sun ZY, Oh KJ, Kim M, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008; 28:52-63.
83. Shen X, Dennison SM, Liu P, et al. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc Natl Acad Sci USA 2010; 107:5972-5977.
84. Ofek G, Zirkle B, Yang Y, et al. Structural Basis for HIV-1 neutralization by 2F5-like Antibodies m66 and m66.6. J Virol 2014; 88:2426-2441.
85. Alam SM, McAdams M, Boren D, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007; 178:4424-4435.
86. Dennison SM, Stewart SM, Stempel KC, et al. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J Virol 2009; 83: 10211-10223.
87. Dennison SM, Sutherland LL, Jaeger FH, et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One 2011; 6:e27824.
88. Kim M, Song L, Moon J, et al. Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. J Biol Chem 2014; 288:31888-31901.
89. Chen Y, Zhang J, Bouton-Verville H, et al. Lipid components in MPER-based immunization regimens are critical for inducing broadly neutralizing antibody responses in 2F5 and 4E10 knockin mice. AIDS Res Human Retr 2013; 29:A20-A120.
90. Shen X, Parks RJ, Montefiori DC, et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009; 83:3617-3625.
91. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
92. Vcelar B, Stiegler G, Wolf HM, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007; 21:2161-2170.
93. Mehandru S, Vcelar B, Wrin T, et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007; 81:11016-11031.
94. Li Y, O'Dell S, Walker LM, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 2011; 85:8954-8967.
95. Ofek G, McKee K, Yang Y, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010; 84:2955-2962.
96. Scherer EM, Leaman DP, Zwick MB, et al. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci USA 2010; 107:1529-1534.
97. Pejchal R, Walker LM, Stanfield RL, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA 2010; 107:11483-11488.
98. Briney BS, Willis JR, Crowe JE Jr. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One 2012; 7:e36750.
99. Georgiev IS, Rudicell RS, Saunders KO, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol 2014; 192:1100-1106.
100. Jardine JG, Sok D, Kalyuzhniy O, et al. Identifying the minimal mutations in VRC01 required for neutralization potency and breadth to inform vaccine design. AIDS Res Human Retr 2013; 29:A14-A114.
101. Jelicic K, Cimbro R, Nawaz F, et al. The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-p1 production and FcRL4 expression. Nat Immunol 2013; 14:1256-1265.
102. Levesque MC, Moody MA, Hwang KK, et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009; 6:e1000107.
103. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31:705-742.
104. Daly J, Bebenek K, Watt DL, et al. Altered Ig hypermutation pattern and frequency in complementary mouse models of DNA polymerase z activity. J Immunol 2012; 188:5528-5537.
105. Jardine J, Julien J-P, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340:711-716.
106. McGuire AT, Hoot S, Dreyer AM, et al. Engineering HIV envelope protein to & activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 2013; 210:655-663.
107. Alam SM, Liao HX, Dennison SM, et al. Differential reactivity germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J Virol 2011; 85:11725-11731.
108. H epitope overlapping those of MPER broad neutralizing antibodies. J Immunol 2014; 192:1693-1706.